Caring Brands enters exclusive global license for Emesyl nausea relief product

Caring Brands, Inc.

Licensed Emesyl OTC nausea product from Itonis; exclusive worldwide rights to manufacture, market, distribute.
8% royalty on net sales; potential to earn 7% of Itonis equity per $200k in sales.
License may terminate if sales ≤$25k for four consecutive quarters after launch.
Global nausea treatment market projected >$6.23B in 2025, per QY Research.
CEO notes expansion of health/wellness portfolio; further updates expected on timelines.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Caring Brands, Inc. entered into License Agreement with Itonis Pharmaceuticals (effective 2025-12-31).

Action: entry
Agreement: license
Counterparty: Itonis Pharmaceuticals
Effective: 2025-12-31

Exact text from the filing

On December 31, 2025, Caring Brands, Inc., a Nevada corporation, (the “ Company ”), entered into a license agreement (the “ License Agreement ”) with Itonis Pharmaceuticals (“ Itonis ”), a Nevada corporation.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Caring Brands, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.